Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bexmarilimab - Faron Pharmaceuticals

Next Previous
Drug Profile

Bexmarilimab - Faron Pharmaceuticals

Alternative Names: Anti-CLEVER-1 antibody - Faron Pharmaceuticals; Clevegen; FP 1305

Latest Information Update: 19 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Faron Pharmaceuticals
  • Class Anti-infectives; Antineoplastics; Antituberculars; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Macrophage stimulants; STAB1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Solid tumours
  • No development reported Tuberculosis
  • Discontinued Immunocompromised infections; Pertussis

Most Recent Events

  • 19 Apr 2024 Discontinued - Preclinical for Immunocompromised infections in Finland (IV) before April 2024 (Faron Pharmaceuticals pipeline, April 2024)
  • 19 Apr 2024 Discontinued - Preclinical for Pertussis in Finland (IV) before April 2024 (Faron Pharmaceuticals pipeline, April 2024)
  • 16 Apr 2024 Faron Pharmaceuticals plans to meet US FDA to accelerate discussions for obtaining marketing approval for Myelodysplastic syndrome
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top